ArticleNature communications2025
GLYCO-BUILD: an enzymatic pipeline for the synthesis of peptides carrying eukaryotic N-glycans.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structures of ALG3/9/12 reveal the assembly logic of the N-glycan oligomannose core.Nature chemical biology · 2026Article
- Functional Engineering of Bioactive Peptides: Chemical Modifications and Synthetic Biology Approaches.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Peptides and proteins containing defined N-glycans hold great promise for biomedicine because the attached glycans engage in specific interactions, influence targeted delivery and folding, and improve pharmacokinetic properties. However, challenges associated with producing homogeneous N-glycoconjugates hinder their wider application. Here, we report the development of GLYCO-BUILD, an enzymatic pipeline that can generate glycopeptides carrying eukaryotic N-glycans at a level of homogeneity not accessible by alternative methodologies. The pipeline recapitulates the endoplasmic reticulum-based steps of the eukaryotic protein N-glycosylation machinery. However, it employs a combination of enzymes of archaeal, bacterial, and eukaryotic origin that are able to process inexpensive phytol instead of the native dolichol as a lipid carrier. GLYCO-BUILD facilitates the synthesis of homogeneous N-glycans ranging from GlcNAc
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.